Viridian Therapeutics appoints Scott Myers as President and CEO, succeeding Jonathan Violin

Viridian Therapeutics, Inc.\DE

Scott Myers, former CEO of AMAG Pharmaceuticals, appointed President & CEO and Class III Director effective Feb 6, 2023.
Founding CEO Jonathan Violin steps down; receives 18-month salary severance, 12-month accelerated option vesting, and consulting role.
Myers granted inducement award of 1,000,000 stock options and 250,000 RSUs, vesting over 4 years with first cliff at 12 months.
Company references positive topline data from Phase 1/2 trial of VRDN-001 for thyroid eye disease (previously filed presentation).

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Myers

President and Chief Executive Officer

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2023-02-06
Filed: February 6, 2023, 6:59 PM ET

appointment of Scott Myers as the Company’s President and Chief Executive Officer, effective immediately.

Appointed

Scott Myers

Class III Director

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2023-02-06
Filed: February 6, 2023, 6:59 PM ET

Mr. Myers was also appointed as a Class III Director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Scott Myers was appointed as President and Chief Executive Officer at Viridian Therapeutics, Inc.\DE.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

appointment of Scott Myers as the Company’s President and Chief Executive Officer, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Scott Myers was appointed as Class III Director at Viridian Therapeutics, Inc.\DE.

Action: appointed
Role: Class III Director

Exact text from the filing

Mr. Myers was also appointed as a Class III Director

View on SEC.gov

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-23-024877

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.